ACAlexandre Cagnard

Alexandre Cagnard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandre Cagnard has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Caroline Bailleux

    Department of Medical Oncology, Antoine Lacassagne Center, University Côte d’Azur, 33 Avenue de Valombrose, 06189 Nice, France

    1 shared publication
  • David Chardin

    Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06100, Nice, France

    1 shared publication
  • Fanny Graslin

    Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), UMR E4320 TIRO-MATOs, Direction de la Recherche Fondamentale (DRF), Institut des Sciences du Vivant Fréderic Joliot, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Faculté de Médecine, Côte d’Azur University, 28 Avenue de Valombrose, CEDEX 2, 06107 Nice, France

    1 shared publication
  • Jean-Marc Ferrero

    Department of Medical Oncology, Antoine Lacassagne Center, University Côte d’Azur, 33 Avenue de Valombrose, 06189 Nice, France

    1 shared publication
  • Jean-Marie Guigonis

    TIRO-MATOs - School of Medicine, University Cote d'Azur, FRANCE

    1 shared publication
  • Jocelyn Gal

    Institut Hospitalo-Universitaire (IHU) RespirERA, University Côte d’Azur, 27 Rue du Professeur Delvalle, 06000 Nice, France

    1 shared publication

Latest Publications

  • Open Access

    Metabolomic Signatures of Scarff–Bloom–Richardson (SBR) Grade in Non-Metastatic Breast Cancer

    by Caroline Bailleux, David Chardin, Jocelyn Gal, Jean-Marie Guigonis, Sabine Lindenthal, Fanny Graslin, Laurent Arnould, Alexandre Cagnard, Jean-Marc Ferrero, Olivier Humbert, et al.

    Purpose: Identification of metabolomic biomarkers of high SBR grade in non-metastatic breast cancer. Methods: This retrospective bicentric metabolomic analysis included a training set (n = 51) and a validation set (n = 49) of breast cancer tumors, all classified as high-grade (grade III) or low-grade (grade I–II). Metabolomes of tissue samples were studied by liquid chromatography coupled with mass spectrometry. Results: A molecular signature of the top 12 metabolites was identified from a database of 602 frequently predicted metabolites. Partial least squares discriminant analyses showed that accuracies were 0.81 and 0.82, the R2 scores were 0.57 and 0.55, and the Q2 scores were 0.44431 and 0.40147 for the training set and validation set, respectively; areas under the curve for the Receiver Operating Characteristic Curve were 0.882 and 0.886. The most relevant metabolite was diacetylspermine. Metabolite set enrichment analyses and metabolic pathway analyses highlighted the tryptophan metabolism pathway, but the concentration of individual metabolites varied between tumor samples. Conclusions: This study indicates that high-grade invasive tumors are related to diacetylspermine and tryptophan metabolism, both involved in the inhibition of the immune response. Targeting these pathways could restore anti-tumor immunity and have a synergistic effect with immunotherapy. Recent studies could not demonstrate the effectiveness of this strategy, but the use of theragnostic metabolomic signatures should allow better selection of patients.